cryoablation for cancer

Displaying 7 studies

  • Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Rochester, MN

    This phase I/II trial studies the best dose and side effects of dendritic cell therapy, cryosurgery and pembrolizumab in treating patients with non-Hodgkin lymphoma. Vaccines, such as dendritic cell therapy made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Cryosurgery kills cancer cells by freezing them. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving dendritic cell therapy, cryosurgery and pembrolizumab may work better at treating non-Hodgkin lymphoma.

  • MR-Guided Cryoablation of Prostate Bed Recurrences Rochester, MN

    The purpose of this research is to see if MR-guided cryoablation can effectively treat prostate tumor recurrences.

  • Study of Cryoablation for Metastatic Lung Tumors Rochester, MN

    The purpose of this study is to evaluate the safety and efficacy of cryoablation therapy used to treat tumors in patients with pulmonary metastatic disease. This study is to enroll patients who will undergo cryoablation of at least 1 metastatic pulmonary tumor that is less than or equal to 3.5cm. Patients will be followed 24 months post their cryoablation procedure.

  • A Study To Examine Quality of Life Assessment in Patients Receiving Cryotherapy for Palliation of Dysphagia in Unresectable Esophageal or Gastroesophageal Junctional Cancer Scottsdale/Phoenix, AZ

    The purpose of this study is to determine the effect of endoscopic cryoablation for lessening the effects of dysphagia on the quality of life (QOL) of patients with unresectable esophageal or gastroesophageal junctional cancer.

  • Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery Rochester, MN

    This phase Ib/II trial studies how well dendritic cell therapy after cryosurgery in combination with pembrolizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Cryosurgery, also known as cryoablation or cryotherapy, kills tumor cells by freezing them. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving dendritic cell therapy after cryosurgery in combination with pembrolizumab may work better in treating patients ...

  • Quantitative Assessment of Tumor Ablation Rochester, MN

    The purpose of this study is to retrospectively analyze potential correlation between ablation zone/margin and tumor recurrence by using the Software Product to quantitatively evaluate diagnostic/pre-operative CT images, intra-operative CT images during ablation procedures, and follow-up CT images; and to apply and evaluate the FDA cleared Software Product during CT-guided ablation procedures for intra-operative monitoring and confirmation.

     

  • A Study to Evaluate the Use of Cryoablation and Anti-PD-L1 Immunotherapy for Triple Negative Breast Cancer (TNBC) Jacksonville, FL

    The purpose of this study is to evaluate whether or not cryoablation will enhance the effects of atezolizumab/nab-paclitaxel (standard of care immunotherapy and chemotherapy) and be safe/feasible for patients with metastatic or unresectable locally advanced triple negative breast cancer (TNBC).

.

Mayo Clinic Footer